key: cord-0929404-2d66ycut
authors: Ibekwe, Elochukwu; Kamdar, Hera A.; Strohm, Tamara
title: Cardio-cerebral infarction in left MCA strokes: a case series and literature review
date: 2021-09-29
journal: Neurol Sci
DOI: 10.1007/s10072-021-05628-x
sha: 63ca49127998b14b0c91d3264776516b1ec4ff25
doc_id: 929404
cord_uid: 2d66ycut

The objective of this manuscript is to describe the challenges of Cardio-Cerebral Infarction (CCI) treatment and to highlight the variable approaches in management. CCI is a rare clinical presentation of simultaneous acute ischemic stroke (AIS) and acute myocardial infarction (AMI) and poses a therapeutic challenge for practitioners. Each disease requires timely intervention to prevent irreversible damage; however, optimal management remains unclear. We describe three cases of CCI. All three patients presented with symptomatic left MCA (M1) occlusion, with ST elevation myocardial infarction (STEMI) and left ventricular apical thrombus. Fibrinolysis and mechanical thrombectomy (MT) were discussed in all cases, but only one patient received alteplase (0.9 mg/kg) and none underwent MT. Percutaneous intervention (PCI) was done in only one case. The two patients that did not receive thrombolysis were treated with modified therapeutic heparin (no bolus), and all received antiplatelet therapy. Ultimately, all three patients passed away. CCI poses a clinical challenge for physicians including (1) optimal strategies to enable swift mechanical reperfusion to both the brain and myocardium; (2) difference in dosage of thrombolytics for AIS versus AMI; (3) risk of symptomatic intracerebral hemorrhage following administration of anticoagulation and/or antiplatelet therapy; and (4) caution with use of thrombolytics in the setting of acute STEMI due to the risk of myocardial rupture. In the absence of high quality evidence and clinical guidelines, treatment of CCI is highly individualized.

Acute ischemic stroke (AIS) and acute myocardial ischemia (AMI) are the leading causes of morbidity and mortality globally [1] . Optimal management prioritizes revascularization via time-sensitive fibrinolysis, percutaneous intervention (PCI), mechanical thrombectomy (MT), and antiplatelet or anticoagulation therapy [2] . Simultaneous presentation of AIS and AMI within 48 h, termed Cardio-Cerebral Infarction (CCI), is quite rare and may be associated with high morbidity and mortality [3] . In patients with CCI, optimal administration of fibrinolytics (dose and agent), timing of intervention (PCI versus MT), treatment with anticoagulation and antiplatelet therapies, and rates of symptomatic ICH are unclear [4, 5] . Thus, optimal management is controversial, with added challenges in the event of a left ventricular (LV) thrombus.

Our objective is to review the epidemiology, pathophysiology, and management of CCI, along with the many management challenges.

This is a case series presenting observational data collected from three patients at The Ohio State University, Wexner Medical Center with acute presentation of CCI within a 1-month period in the year 2020. Due to the COVID-19 pandemic, verbal consent was obtained via telephone. Furthermore, a literature review of CCI was performed in PubMed and EMBASE. No time limitation filter was applied. The following MeSH terms were used as follows: "Cardio cerebral infarct," "stroke and MI," "stroke and myocardial infarction," "STEMI and stroke," "NSTEMI and stroke." Articles included, contained a full description of the case, outlining the presentation and management steps, and with evidence of both cerebral and cardiac infarction within 48 h.

We describe three cases of CCI in a 43-year-old male, a 72-year-old male, and an 80-year-old female ( Table 1) . All three patients presented with symptomatic proximal left MCA (M1) occlusion ( Fig. 1) , ST elevation myocardial infarction (STEMI) (Fig. 2) , and left ventricular apical thrombus. Examinations revealed full left MCA syndrome with aphasia and R sided weakness . Interventional therapies such as alteplase and mechanical thrombectomy (MT) were discussed in all cases, but alteplase was utilized in only one. In one case, left heart catheterization was done without intervention/stenting. Two patients received modified therapeutic heparin (no bolus) for LV thrombus; all patients received antiplatelet therapy with aspirin and/or clopidogrel. Ultimately, all three patients expired.

A 43-year-old right handed male with past medical history of gun-shot wound, and nephrolithiasis presented to our medical center with symptoms of right hemiplegia and global aphasia (NIHSS 25) with unknown last known well (LKW). Vitals on admission were stable. Labs revealed Troponin of 49 ng/ml, with ST elevation in leads II, III, aVF, V2-6 ( Fig. 2 ). Left heart coronary (LHC) angiography revealed 60% stenosis with associated non-atherosclerotic showed core of 55 cc with a mismatch volume and ratio of 41 cc and 1.7 respectively. Given unknown LKW, with unavailability of MRI FLAIR-diffusion mismatch protocol at our institution, acute management ischemic stroke did not include alteplase, nor MT. Due to STEMI on presentation, he was loaded with aspirin and Ticagrelor, with only aspirin continued after, and taken for emergent percutaneous coronary angioplasty. PCI was aborted due to need of bolus heparin prior to catheterization, and dual anti-platelet therapy "DAPT" post-catheterization, which would put him at increased risk of hemorrhagic conversion. Subsequent medical management was optimized for acute ischemia with goal directed medical therapy (GDMT) including aspirin. Immediate anticoagulation was not started for LV thrombus given risk of hemorrhagic conversion of large acute ischemic stroke. On day 5 of admission, "neuro scale" heparin drip (aPTT goal 52-75, no bolus) was started for LV thrombus, without transitioning to "cardiac scale" (aPTT goal of 72-95). His hospital course was further complicated by wide complex tachycardia secondary to known LAD occlusion, which was medically managed with lidocaine and amiodarone. He was ultimately transitioned to comfort care and passed away on day 7 of admission.

An 80-year-old right handed female with past medical history of COPD, and tobacco use presented initially to an outside hospital with right hemiplegia and global aphasia (NIHSS 23) with LKW ≤ 4.5 h. She was given alteplase at 3.2 mg bolus with infusion at 28.7 mg/h, and transferred to OSU for further evaluation. On arrival, CTA revealed left M1 occlusion and CT Perfusion revealed core of 28 cc, mismatch volume and ratio of 8 cc and 1.3 respectively. She was deemed to not be a MT candidate given her low mismatch ratio. EKG revealed an acute STEMI with mild elevation of Troponin to 1.1 ng/ml and ST elevation in leads V3-5 ( Fig. 2) . Echocardiography showed an EF of 29% and apical LV thrombus.

Stroke management included intravenous (IV) alteplase (0.9 mg/kg), aspirin at 24-h post alteplase, statin, blood pressure control, and preventing edema by induced hypernatremia (140-145 mmol/L) using 0.9% normal saline. Due to down-trending troponin, lack of new EKG changes, and the need for DAPT increasing the risk of hemorrhagic conversion, she was not offered PCI, nor started on a heparin drip. Her AMI was managed with GDMT. Given her comorbidities, age, and wishes, she was transitioned to comfort care and discharged to hospice with NIHSS of 25. She passed away at day 3 of discharge.

A 72-year-old right handed male with past medical history of pancreatitis presented with right hemiplegia and facial droop (NIHSS 27) with LKW > 4.5 h. Vitals were pertinent for tachycardia to 110 on admission. Labs revealed Troponin of 6.5 ng/ml. His EKG showed an acute STEMI in the anteroseptal region (Fig. 2) . CTA showed a Left M1 occlusion. CT perfusion showed a core of 12 cc with mismatch volume and ratio of 36 cc and 4.0 respectively. Echocardiogram revealed an EF 30% and LV thrombus. As with the cases above, etiology of acute cerebral and myocardial ischemia was presumed secondary to his LV thrombus.

His AIS was managed medically with dual anti-platelet with aspirin/ clopidogrel, and statin. He did not receive alteplase due to being outside the window, nor did he get mechanical thrombectomy due to inability to perform the procedure per neurosugery. His AMI was managed medically, with non-bolus "neuro scale" heparin drip and antiplatelet and statin. His hospital course was complicated by ventricular tachycardia. He continued to have significant neurological disability with significant dysarthria and dysphagia requiring PEG tube. Family elected to transition him to comfort care and he passed away on hospital day 7.

The incidence and prevalence of simultaneous AIS and AMI are unknown due to rarity of presentation. The reported incidences in literature are from observational studies and case reports. Rokey et al. found 58% prevalence of CAD in patients presenting with AIS/ TIA [6] . Chin et al. reported the incidence of CCI as 12.7% in geriatric patients who were screened for AMI within 72 h of admission for acute stroke [7] . Findings from the Global Registry of Acute Coronary Event (GRACE) trial reported an incidence of in-hospital stroke as 0.9% in a cohort of patients presenting with acute coronary syndrome, with a higher incidence in STEMI compared to non-STEMI [8] . The most recent data in 2017 from Yeo et al. showed that 6% of patients with acute stroke had ST segment elevation [9, 10] . Notably, these reported incidences are mostly for non-synchronous presentation, rather than simultaneous presentation of AIS and AMI.

There are four major pathophysiologic mechanisms of CCI including (1) cardioembolic, (2) neurogenic stunned myocardium, (3) hypotensive, and (4) dissection.

Cardioembolism to the cerebral and myocardial arteries can lead to AIS and AMI and is typically secondary to either LV thrombus formation associated with heart failure, atrial fibrillation, or paradoxical embolization via patent foramen ovale in patients with RV thrombus or deep vein thrombosis [9, [11] [12] [13] .

Ischemic infarcts, especially ones involving the insular cortex, are associated with higher risk of neurogenic stunned myocardium and arrhythmias which can mimic ST-elevation myocardial ischemia [14, 15] . This myocardial stunning is a result of dysfunction of CNS structures that control autonomic nervous system regulation of myocardium leading to sympathetic dominance. At the molecular level, there is reduced duration of delayed rectifier K + channels and alteration in L-type Ca ++ channels. Alterations of K + channels lead to shortened diastolic interval (DI), reduced action-potential duration (APD), and insufficient myocardial refractory period prior to generation of new stimulus. Concurrently, abnormal sympathetic nervous system (SNS) stimulation of L-type Ca ++ channels triggers frequent afterdepolarization. Ultimately, this affects myocardium rhythm and integrity, predisposing to wall motion abnormalities and formation of cardiac thrombus [15, 16] .

Another reported mechanism of CCI is hypotension, which occurs as a sequela of AMI causing dysregulation of cerebral blood flow leading to watershed infarcts [3, 9] . Although rare, extension of an ascending aortic dissection to the coronary ostia and a subsequent extension to the carotid, vertebral, or basilar arteries may also explain the simultaneous occurrence of a cerebral and a coronary infarction [17] .

Management of AIS prioritizes thrombolytic administration and revascularization with MT. Alteplase is administered if ischemic stroke is within 4.5 h of LKW (Table 2) , and MT is considered if there is a large vessel occlusion within 24 h. Although less commonly used in the USA, tenectaplase, which is more fibrin-specific and has a longer mechanism of action, may be considered well [18] .

Management of AMI is similar, prioritizing timely restoration of blood flow to coronary vessels using PCI and/or fibrinolytic therapy [22, 23] . PCI is the preferred method of revascularization when it can be performed within 120 min, and in patients presenting with AMI within 12 h. Fibrinolysis via tenecteplase, alteplase, or streptokinase is indicated for symptom onset within 12 h followed by transfer for PCI, or if PCI cannot be completed within 120 min (Table 2) [19, 20] . Peri-procedural heparin and dual antiplatelet therapy are recommended following PCI.

Management of CCI is individualized (Table 3) . Among the twenty-five cases reviewed within the literature review performed, 7 (28%) utilized MT, 15 (60%) underwent PCI, 9 (36%) received fibrinolysis (alteplase), and 12 (48%) had concurrent cardiac thrombus. 4 (16%) received mono antiplatelet (MAP) only, 3 (12%) DAP only, 4 (16%) MAP plus AC, 3 (12%) DAP plus AC, 10 (40%) heparin therapy, and 8 (32%) AC other than, and/ or with heparin. Outcomes were reported in 16 (64%), with 4 (16%) and 6 (24%) having MRS ≤ 3 at 1 and 3 months respectively. Approximately 20% expired during hospitalization. This highlights the inconsistency in practice and outcomes, thus the need for clear guidelines.

The management of AIS in the setting of LV thrombus is centered on the decision of anticoagulation timing, since much of the cardiac literature recommends prompt treatment of thrombus. Management of LV thrombus includes anticoagulation therapy for 3-6 months with serial echocardiogram to monitor resolution of thrombus. Anticoagulation can be discontinued after 6 months if there is resolution of LV thrombus, low risk of thrombus re-formation, and no significant wall motion abnormality. Timing on initiation of AC in setting of CCI has no clear guidelines with variations as noted in Table 3 .

Dilemmas associated with management of CCI include the following: Table 2 Dose of fibrinolytic therapy for acute ischemic stroke and acute myocardial ischemia [19] [20] [21] LVO large vessel occlusion Acute ischemic stroke Acute myocardial ischemia Alteplase -0.9 mg/kg -10% given as initial bolus over 1 min -90% as a continuous infusion over 60 min (Table 2 ). 2. The use of PCI with stenting requires peri-procedural heparin infusion, and prolonged use of dual-anti platelet therapy. This has been associated with increased risk of hemorrhagic conversion in AIS, but evidence is limited regarding long-term clinical outcomes [40] . 3. Caution with use of thrombolytics in the setting of acute STEMI due to the risk of myocardial rupture [41] .

Currently, data on risk factors associated with hemorrhagic transformation in the setting of CCI is lacking. A small retrospective study from Schmidbauer et al. did not show increased incidence of ICH in AIS patients treated with PCI compared to those not getting PCI [42] . Several trials, such as Troponin Elevation in Acute Ischemic Stroke (TRELAS), which evaluated the diagnostic yield of troponin levels in AIS, did not report rates of symptomatic ICH. We await the results of ongoing trial Prediction of Acute Coronary Syndrome in Acute Ischemic Stroke (PRAISE), which is assessing the diagnostic yield of biomarkers, clinical scores, signs and symptoms, EKG, and echocardiography findings to identify patients in need of PCI. We hope that rates of hemorrhagic transformation are reported. Given the lack of high quality data, clinicians should individualize management-prioritizing fibrinolytic therapy and mechanical revascularization-with full assessment of bleeding risk, and other comorbidities.

Regarding CCI necessitating acute intervention, we propose combined treatment of myocardial and cerebral vascular territories with administration of alteplase (0.9 mg/ kg) followed by PCI with stenting if indicated [9] . Concomitant need for mechanical cerebral thrombectomy can then be assessed using cerebral angiogram. Another approach could be combining mechanical thrombectomy with PCI in select cases, with close monitoring of neurological status to detect symptomatic hemorrhagic conversion.

This case series only reports observational findings and is not structured to evaluate for associations between different management options and clinical outcome (i.e., symptomatic ICH, morbidity/mortality). Furthermore, since all of the patients were transitioned to comfort care within a week of admission, it is impossible to predict overall outcomes. Lastly, the search strategy and inclusion criteria for the literature review focused on the current definition of CCI necessitating AMI and AIS within 48 h of each other, leading to exclusion of many studies.

Appropriate management of CCI poses a great challenge for practitioners. Clinicians must be mindful of the following: (1) treatment strategies to enable swift mechanical reperfusion to both the brain and myocardium; (2) risk of cardiac tamponade and myocardial rupture with intravenous thrombolytic therapy; (3) difference in dosage of thrombolytics for AIS versus AMI; and (4) risk of symptomatic intracerebral hemorrhage following administration of anticoagulation and/or antiplatelet therapy. There is an urgent need for future studies to guide optimal management.

Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the

Concomitant acute right ventricular infarction and ischemic cerebrovascular stroke; possible explanations

Radiological predictors of hemorrhagic transformation after acute ischemic stroke: An evidence-based analysis

Recent myocardial infarction is associated with increased risk in older adults with acute ischemic stroke receiving thrombolytic therapy

Coronary artery disease in patients with cerebrovascular disease: a prospective study

Myocardial infarction coincident with cerebrovascular accidents in the elderly

Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a global registry of acute coronary events

Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

Incidence and outcomes of myocardial infarction in patients admitted with acute ischemic stroke

Left ventricular thrombus formation after acute myocardial infarction

Epidemiology of myocardial infarction caused by presumed paradoxical embolism via a patent foramen ovale

Acute myocardial infarction and transient ischemic attack in a patient with lone atrial fibrillation and normal coronary arteries

Left insular stroke is associated with adverse cardiac outcome

Tako-tsubo syndrome as a consequence and cause of stroke

Cardiac dysfunction in neurocritical care: an autonomic perspective

Aortic dissection associated with acute myocardial infarction and stroke found at autopsy

Evidence that tenecteplase is non-inferior to alteplase for acute ischemic stroke

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial

Tenecteplase thrombolysis for acute ischemic stroke

ESC Guidelines for the Management of acute myocardial infarction in patients presenting with STsegment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Acute stroke with concomitant acute myocardial infarction: Will you thrombolyse?

Hyperacute simultaneous cardiocerebral infarction: rescuing the brain or the heart first? Front Neurol 8:664

Simultaneous cardio-cerebral infarction in the coronavirus disease pandemic era: a case series

Nonhyperacute synchronous cardio-cerebral infarction treated by double intervensionist therapy

Double the trouble: acute coronary syndrome and ischemic stroke in polycythemia vera

The clot strikes thrice: case report of a patient with 3 concurrent embolic events

The role of anticoagulation in post-COVID-19 concomitant stroke, myocardial infarction, and left ventricular thrombus: a case report

Cardioembolic acute myocardial infarction and stroke in a patient with persistent atrial fibrillation

Simultaneously presented acute ischemic stroke and non-st elevation myocardial infarction in a patient with paroxysmal atrial fibrillation

Reperfusion strategy for simultaneous ST-segment elevation myocardial infarction and acute ischemic stroke within a time window

Simultaneous onset of myocardial infarction and ischemic stroke in a patient with atrial fibrillation: multiple territory injury revealed on angiography and magnetic resonance

Acute embolic cerebral infarction and coronary artery embolism in a patient with atrial fibrillation caused by similar thrombi

Endovascular therapy for concurrent cardio-cerebral infarction in a patient with trousseau syndrome

A case of cardiac tamponade during the treatment of simultaneous cardio-cerebral infarction associated with atrial fibrillation -case report

Simultaneous cardio-cerebral embolization associated with atrial fibrillation: a case report

Concurrent stroke and ST-elevation myocardial infarction: is it a contraindication for intravenous tenecteplase?

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the strokeacute ischemic NXY treatment (SAINT) I and SAINT II trials

Intravenous thromblysis for acute ischemic stroke after recent myocardial infarction. Case Series and Systematic Review

Low rate of intracerebral hemorrhage after cardiac catheterization in patients with acute ischemic stroke in a large case series

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations